Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Meeting Board of Directors of the Company held today ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evoq Remedies Ltd held a board meeting on March 31, 2025, where it approved the appointment of Ms. Pushpa Joshi (DIN: 06838093) as an Additional Non-Executive Independent Director. In the same meeting, the board accepted the resignation of Ms. Aesha Harsh Shah (DIN: 10423365) from the position of Independent Director, effective March 31, 2025, citing personal reasons. Ms. Shah confirmed there are no other material reasons for her exit beyond personal reasons. Following these changes, the Audit Committee and Nomination & Remuneration Committee were reconstituted, with Ms. Joshi joining both committees. The new appointee has about six years of experience in accounting, financial management, and office administration.
This is a routine board-level transition involving one Independent Director exiting for personal reasons and another being appointed in her place. The committees have been reconstituted to maintain compliance, so there is no material impact on shareholders or the stock price from this change.